Currently out of the existing stock ratings of Katie Tryhane, 1 are a HOLD (7.14%), 11 are a BUY (78.57%), 2 are a SELL (14.29%).

Katie Tryhane

Work Performance Price Targets & Ratings Chart

Analyst Katie Tryhane, carries an average stock price target met ratio of 62.5% that have a potential upside of 11.89% achieved within 251 days. Previously, Katie Tryhane worked at CREDIT SUISSE.

Katie Tryhane’s has documented 28 price targets and ratings displayed on 8 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRL, Charles River Laboratories at 25-Aug-2022.

Wall Street Analyst Katie Tryhane

Analyst best performing recommendations are on MRVI (MARAVAI LIFESCIENCES HOLDINGS ).
The best stock recommendation documented was for MRVI (MARAVAI LIFESCIENCES HOLDINGS ) at 8/11/2021. The price target of $54 was fulfilled within 1 day with a profit of $4 (8%) receiving and performance score of 80.

Average potential price target upside

of $43.93 (41.73%) on FLGT (FULGENT GENETICS).
of $24.64 (12.84%) on ZTS (ZOETIS).
of $14.91 (17.52%) on SYNH (SYNEOS HEALTH).

CRL Charles River Laboratories DHR Danaher FLGT Fulgent Genetics IDXX IDEXX Laboratories MRVI Maravai Lifesciences Holdings SYNH Syneos Health ZTS Zoetis SOPH Sophia Genetics SA

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tejas Savant (MORGAN STANLEY)